Dr. Langer on the Impact of Frontline Immunotherapy in Lung Cancer

Video

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

Corey J. Langer, MD, director, Thoracic Oncology, Abramson Cancer Center, professor of medicine, Perelman School of Medicine, University of Pennsylvania, discusses the impact of frontline immunotherapy in lung cancer.

The introduction of immunotherapy upfront has changed the treatment paradigm, Langer says. Only a few years ago, the then standard of care docetaxel was either relegated to the third-line setting or rendered clinically irrelevant. In nonsquamous disease, platinum-based chemotherapy was generally administered in the frontline setting, followed by immunotherapy, regardless of PD-L1 status. If immunotherapy failed to show efficacy, the patient would go on to receive docetaxel and ramucirumab (Cyramza).

In the second-line setting, there are some cases where a physician would go with docetaxel alone—for example, if there’s ongoing bleeding. An agent such as gemcitabine could even be used as an alternative to ramucirumab.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,